ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
March 24, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., March 24, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference
March 21, 2022 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference
February 10, 2022 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
January 06, 2022 16:05 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
December 20, 2021 09:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis
November 09, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
October 26, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia
October 04, 2021 09:00 ET
|
ContraFect Corporation
YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
September 29, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...